Pre-filled "Ask AI" links can save vendor domains as trusted sources, potentially biasing future answers without malware or ...
Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today announced approval to initiate a Phase I ...
ANAHEIM, CA / ACCESS Newswire / August 4, 2026 /Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract ...
Enterprise AI security report from Akamai documents vibe hacking, CursorJacking, and CometJacking -- new attack classes ...
Enterprises are racing to plug Large Language Models (LLMs) into their internal systems CRMs, ticketing tools, code ...
DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- ...
The refreshed Mercedes-Benz S-Class is coming to Australia soon with updated powertrains, bolder styling, and more technology ...
Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee ...
US manufacturers evaluate LSR tooling partners on technical capabilities, regulatory compliance, and total cost of ownership.
Long-acting GLP-1 drug TE-8105, developed by Taiwan biotech Immunwork, confirmed a five-day plasma half-life in first-in-human trials using a dual fatty acid bundle approach not used by any approved ...
The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.
This humble diesel has been motivating everything from MPVs to Mercs for decades, and we figure it's time the spotlight was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results